Tumor infiltrating M2 macrophages could predict biochemical recurrence of localized prostate cancer after radical prostatectomy-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Tumor infiltrating M2 macrophages could predict biochemical recurrence of localized prostate cancer after radical prostatectomy

Published:2019-11 Issue:1 Volume:384 Page:111588
ISSN:0014-4827
Container-title:Experimental Cell Research
language:en
Short-container-title:Experimental Cell Research

Author:

Zhang Qijie,Xia Jiadong,Wang Yi,Zhang Jiayi,Ji Chengjian,Cong Rong,Wang Yamin,Song Ninghong

Funder

Medical key talent of Jiangsu Province

National Natural Science Foundation of China

Publisher

Elsevier BV

Subject

Cell Biology

Reference30 articles.

1. Prognostic value of inflammation in prostate cancer progression and response to therapeutic: a critical review;Sciarra;J. Inflamm.,2016

2. Management of biochemical recurrence after primary curative treatment for prostate cancer: a review;Artibani;Urol. Int.,2018

3. Prostate specific antigen only progression of prostate cancer;Moul;J. Urol.,2000

4. EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent;Mottet;Eur. Urol.,2017

5. Microenvironmental regulation of tumor progression and metastasis;Quail;Nat. Med.,2013

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immune cell infiltration-based prognosis in prostate cancer: a review of current knowledge;Bulletin of the National Research Centre;2023-08-25

2. High infiltration of CD209+ dendritic cells and CD163+ macrophages in the peritumor area of prostate cancer is predictive of late adverse outcomes;Frontiers in Immunology;2023-06-26

3. CircSMARCC1 facilitates tumor progression by disrupting the crosstalk between prostate cancer cells and tumor-associated macrophages via miR-1322/CCL20/CCR6 signaling;Molecular Cancer;2022-09-01

4. Exosomes derived from M2 type tumor-associated macrophages promote osimertinib resistance in non-small cell lung cancer through MSTRG.292666.16-miR-6836-5p-MAPK8IP3 axis;Cancer Cell International;2022-02-15

5. Identification and validation of a novel signature for prediction the prognosis and immunotherapy benefit in bladder cancer;PeerJ;2022-01-25

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3